The Zhitong Finance App learned that Citi released a research report saying that Hewang Pharmaceutical (00013.HK) business operations have seen an inflection point from innovation, clinical progress, and sales recovery. The bank reaffirmed the “buy/high risk” rating, with a target price of HK$40.1.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.